Skip to main contentSkip to navigationSkip to search
SEK  %

Interim Report for Enzymatica AB (publ) January-March 2016

Regulatory information
Higher sales and improved operating profit

Higher sales and improved operating profit


  • Net sales reached SEK 8.4 (7.0) million.
  • Loss after tax came in at SEK -8.1 (-9.0) million. The loss was impacted by expenses in the amount of SEK -1.5 million for the upcoming acquisition of Zymetech.
  • Earnings per share were SEK -0.32 (-0.36).
  • Cash and cash equivalents amounted to SEK 7.2 (31.8) million at the end of Q1.

Significant events in Q1

  • Enzymatica signed an agreement to acquire Icelandic company Zymetech via a non-cash issue.
  • An extraordinary meeting approved the acquisition of Zymetech on February 15.
  • The Board of Directors of Enzymatica AB (publ) ("the Company") resolved to submit a proposal to an extraordinary general meeting on April 14 for a new share issue worth approximately SEK 60 million with preemptive rights for existing shareholders and authorization for a private placement of a maximum of 17.5 million shares.

Significant events after the end of the period

  • Enzymatica completed its acquisition of Zymetech ehf. on April 1 after the terms of the transaction were met in March. The extraordinary general meeting on April 14 approved the preemptive rights issue and the proposed authorization for the board to conduct a private placement.
Financial ratios      
(SEK million) Jan-Mar
Full year
Net sales 8.4 7.0 27.9
Gross margin, % 61 72 70
Operating profit/loss -7.7 -9.1 -40.4
Cash flow from operating activities -5.1 -4.9 -37.7
Average number of employees 16 15 16

CEO statement: A quarter characterized by the acquisition and planned integration of Zymetech

Q1 was characterized by Enzymatica's acquisition of Iceland-based company and partner Zymetech. The acquisition serves as a key complement to our business, giving Enzymatica access to patent protection for ColdZyme® throughout Europe and a dozen or so additional countries. This gives us the ability to offer distributors exclusive distribution rights, which will facilitate our international expansion. We also get control over enzyme production and access to Zymetech's research expertise in enzyme technology and the company's research portfolio.

The transaction was completed on April 1 and we are already pushing full speed ahead with the integration of product development, regulatory issues, quality processes, production, marketing and sales. This is an aggressive acquisition to facilitate and accelerate our international expansion. Cost synergies are thus less important. We will avoid overlapping activities in regards to new product lines and patent applications. A key milestone in connection with the acquisition was the approval of the extraordinary general meeting on April 14 for the preemptive rights issue of SEK 60 million. The issue is fully underwritten through subscription and underwriting commitments from existing shareholders and external underwriters. The issue creates financial stability and an opportunity to steer our business in a more aggressive direction with a primary focus on expansion outside of the Nordic region.

I am glad that we were able to boost sales in Q1 in comparison to the strong first quarter of 2015. Our operating loss improved as well thanks to a cost-cutting program we initiated in the second half of 2015, resulting in lower staff and marketing expenses.

The Swedish market still accounts for the largest share of Enzymatica's sales and the smaller package ColdZyme OneCold has exhibited solid volume growth. We are excited that sales on markets outside of Sweden are now beginning to take off with follow-on orders from our distributors in Finland and Spain.

Our patient study COLDPREV II was kicked off in late March at Imperial College London and we expect the study to be complete by the end of 2016 at the latest. Discussions with potential international distributors are in progress and are our highest priority going forward.

Fredrik Lindberg CEO

For questions about this report, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:

Bengt Jöndell, CFO, Enzymatica AB
Tel: +46 (0)703-77 71 70 | Email: